There are 2137 resources available
601TiP - First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours
Presenter: Hans Gelderblom
Session: E-Poster Display
Resources:
Abstract
602TiP - A first-in-human study of NOV1601 (CHC2014), small-molecule inhibitor of TRK family proteins, in adult patients with solid organ malignancies
Presenter: Tak Yun
Session: E-Poster Display
Resources:
Abstract
603TiP - Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
Presenter: Martin Schuler
Session: E-Poster Display
Resources:
Abstract
604TiP - ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
Presenter: Serge Leyvraz
Session: E-Poster Display
Resources:
Abstract
605TiP - Targeting anti-cancer drug resistance in gastro-intestinal cancer: Inhibition of the SRPK1 kinase and degradation of the ABCG2 drug efflux pump
Presenter: Morten Ladekarl
Session: E-Poster Display
Resources:
Abstract
606P - Novel miRNA-based assay for GEP-NENs management
Presenter: Martine Bocchini
Session: E-Poster Display
Resources:
Abstract
607P - Prognostic value of early total, free and bound to lipoprotein fractions plasma mitotane measurements in advanced adrenocortical carcinoma at the time of mitotane initiation: A prospective study of the ENDOCAN-COMETE-cancer network
Presenter: Annabelle Naman
Session: E-Poster Display
Resources:
Abstract
608P - METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours
Presenter: Joao Glasberg
Session: E-Poster Display
Resources:
Abstract
619P - Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network
Presenter: Alfredo Berruti
Session: E-Poster Display
Resources:
Abstract
620P - Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
Presenter: Emanuela Romano
Session: E-Poster Display
Resources:
Abstract